Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa
- 1 November 1995
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 39 (11), 2411-2414
- https://doi.org/10.1128/aac.39.11.2411
Abstract
Previous studies have demonstrated synergy between an aminoglycoside and a beta-lactam for treating Pseudomonas aeruginosa infections. Cystic fibrosis patients are prone to infection by this bacterium, which becomes very resistant with recurrent antibiotic treatments. The purpose of this study was to evaluate the susceptibility patterns of 122 isolates of P. aeruginosa isolated from cystic fibrosis patients to five individual antibiotics (tobramycin, ceftazidime, piperacillin, ticarcillin, and imipenem) and to four antibiotic combinations (tobramycin associated with one of the other antibiotics). Strains were selected because of their resistance to individual antimicrobial agents, which ranged from 21.3% for imipenem to 56.5% for tobramycin. By using an automated broth microdilution method, we were able to demonstrate synergy against 39 strains (32%) with tobramycin-ticarcillin, against 38 strains (31%) with tobramycin-piperacillin, against 47 strains (39%) with tobramycin-ceftazidime, and against 23 strains (19%) with tobramycin-imipenem. Of the 122 isolates, 77 (63%) were rendered significantly susceptible to at least one of the four antibiotic combinations by synergy. These results suggest that when appropriate technology is available, susceptibility to antibiotic combinations greatly improves the guide to antibiotic therapy for infections due to P. aeruginosa in cystic fibrosis patients.Keywords
This publication has 16 references indexed in Scilit:
- The changing epidemiology of cystic fibrosisThe Journal of Pediatrics, 1993
- Emergence of antibiotic resistance amongst Pseudomonas aeruginosa isolates from patients with cystic fibrosisJournal of Antimicrobial Chemotherapy, 1993
- Antimicrobial agent therapy for Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 1991
- In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosisAntimicrobial Agents and Chemotherapy, 1990
- The effect of rifampicin on the in-vitro activity of cefpirome or ceftazidime in combination with aminoglycosides against Pseudomonas aeruginosaJournal of Antimicrobial Chemotherapy, 1990
- Identification of the Cystic Fibrosis Gene: Genetic AnalysisScience, 1989
- Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosisThe Journal of Pediatrics, 1988
- Determination of synergy by two methods with eight antimicrobial combinations against tobramycin-susceptible and tobramycin-resistant strains of pseudomonasDiagnostic Microbiology and Infectious Disease, 1987
- Pseudomonas cepacia infection in cystic fibrosis: An emerging problemThe Journal of Pediatrics, 1984
- A Method for Testing for Synergy with Any Number of AgentsThe Journal of Infectious Diseases, 1978